Xencor, Inc. and Boehringer Ingelheim have entered into a collaboration to optimize therapeutic monoclonal antibodies with improved clinical performance. BI will apply Xencor’s XmAb technology platform, including proprietary Fc domains, to maximize the efficacy of BI’s antibody drug candidates against selected targets of interest. Xencor’s XmAb Fc domains are designed to enhance the therapeutic properties of antibodies including sustained half-life, increased structural stabili...